134 related articles for article (PubMed ID: 22921316)
1. In vivo electroporation improves therapeutic potency of a DNA vaccine targeting hepadnaviral proteins.
Khawaja G; Buronfosse T; Jamard C; Abdul F; Guerret S; Zoulim F; Luxembourg A; Hannaman D; Evans CF; Hartmann D; Cova L
Virology; 2012 Nov; 433(1):192-202. PubMed ID: 22921316
[TBL] [Abstract][Full Text] [Related]
2. Enhanced magnitude and breadth of neutralizing humoral response to a DNA vaccine targeting the DHBV envelope protein delivered by in vivo electroporation.
Khawaja G; Buronfosse T; Jamard C; Guerret S; Zoulim F; Luxembourg A; Hannaman D; Evans C; Hartmann D; Cova L
Virology; 2012 Mar; 425(1):61-9. PubMed ID: 22284894
[TBL] [Abstract][Full Text] [Related]
3. In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes.
Saade F; Buronfosse T; Guerret S; Pradat P; Chevallier M; Zoulim F; Jamard C; Cova L
J Viral Hepat; 2013 Apr; 20(4):e56-65. PubMed ID: 23490390
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of neutralizing humoral response of DNA vaccine against duck hepatitis B virus envelope protein by co-delivery of cytokine genes.
Saade F; Buronfosse T; Pradat P; Abdul F; Cova L
Vaccine; 2008 Sep; 26(40):5159-64. PubMed ID: 18554756
[TBL] [Abstract][Full Text] [Related]
5. Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection.
Miller DS; Halpern M; Kotlarski I; Jilbert AR
Virology; 2006 May; 348(2):297-308. PubMed ID: 16469347
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection.
Thermet A; Buronfosse T; Werle-Lapostolle B; Chevallier M; Pradat P; Trepo C; Zoulim F; Cova L
J Gen Virol; 2008 May; 89(Pt 5):1192-1201. PubMed ID: 18420797
[TBL] [Abstract][Full Text] [Related]
7. Progress in DNA vaccine for prophylaxis and therapy of hepatitis B.
Thermet A; Rollier C; Zoulim F; Trepo C; Cova L
Vaccine; 2003 Jan; 21(7-8):659-62. PubMed ID: 12531335
[TBL] [Abstract][Full Text] [Related]
8. The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines.
Feng F; Teoh CQ; Qiao Q; Boyle D; Jilbert AR
Vaccine; 2010 Oct; 28(46):7436-43. PubMed ID: 20833122
[TBL] [Abstract][Full Text] [Related]
9. DNA vaccines expressing the duck hepatitis B virus surface proteins lead to reduced numbers of infected hepatocytes and protect ducks against the development of chronic infection in a virus dose-dependent manner.
Miller DS; Kotlarski I; Jilbert AR
Virology; 2006 Jul; 351(1):159-69. PubMed ID: 16624364
[TBL] [Abstract][Full Text] [Related]
10. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR
Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204
[TBL] [Abstract][Full Text] [Related]
11. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein.
Rollier C; Sunyach C; Barraud L; Madani N; Jamard C; Trepo C; Cova L
Gastroenterology; 1999 Mar; 116(3):658-65. PubMed ID: 10029625
[TBL] [Abstract][Full Text] [Related]
12. Protective efficacy of DNA vaccines against duck hepatitis B virus infection.
Triyatni M; Jilbert AR; Qiao M; Miller DS; Burrell CJ
J Virol; 1998 Jan; 72(1):84-94. PubMed ID: 9420203
[TBL] [Abstract][Full Text] [Related]
13. IFN-gamma increases efficiency of DNA vaccine in protecting ducks against infection.
Long JE; Huang LN; Qin ZQ; Wang WY; Qu D
World J Gastroenterol; 2005 Aug; 11(32):4967-73. PubMed ID: 16124047
[TBL] [Abstract][Full Text] [Related]
14. Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect on intrahepatic-viral DNA, RNA, and protein expression.
Luscombe C; Pedersen J; Uren E; Locarnini S
Hepatology; 1996 Oct; 24(4):766-73. PubMed ID: 8855174
[TBL] [Abstract][Full Text] [Related]
15. Antiviral effects of PNA in duck hepatitis B virus infection model.
Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
[TBL] [Abstract][Full Text] [Related]
16. Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity.
Wang J; Gujar SA; Cova L; Michalak TI
J Virol; 2007 Jan; 81(2):903-16. PubMed ID: 17079319
[TBL] [Abstract][Full Text] [Related]
17. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.
Le Mire MF; Miller DS; Foster WK; Burrell CJ; Jilbert AR
J Virol; 2005 Oct; 79(19):12242-52. PubMed ID: 16160150
[TBL] [Abstract][Full Text] [Related]
18. The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis.
Reaiche GY; Le Mire MF; Mason WS; Jilbert AR
Virology; 2010 Oct; 406(2):286-92. PubMed ID: 20705309
[TBL] [Abstract][Full Text] [Related]
19. [Establishment of an in vivo model for duck hepatitis B virus infection using Hubei duckling].
Hu Q; Fang Y; Zhang ZM; Zhang XY; Zhang ZH; Yang DL
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):113-5. PubMed ID: 18574531
[TBL] [Abstract][Full Text] [Related]
20. Rise in gamma interferon expression during resolution of duck hepatitis B virus infection.
Narayan R; Buronfosse T; Schultz U; Chevallier-Gueyron P; Guerret S; Chevallier M; Saade F; Ndeboko B; Trepo C; Zoulim F; Cova L
J Gen Virol; 2006 Nov; 87(Pt 11):3225-3232. PubMed ID: 17030856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
